Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
PLoS One ; 7(4): e35485, 2012.
Article in English | MEDLINE | ID: mdl-22536391

ABSTRACT

Based on the partial efficacy of the HIV/AIDS Thai trial (RV144) with a canarypox vector prime and protein boost, attenuated poxvirus recombinants expressing HIV-1 antigens are increasingly sought as vaccine candidates against HIV/AIDS. Here we describe using systems analysis the biological and immunological characteristics of the attenuated vaccinia virus Ankara strain expressing the HIV-1 antigens Env/Gag-Pol-Nef of HIV-1 of clade C (referred as MVA-C). MVA-C infection of human monocyte derived dendritic cells (moDCs) induced the expression of HIV-1 antigens at high levels from 2 to 8 hpi and triggered moDCs maturation as revealed by enhanced expression of HLA-DR, CD86, CD40, HLA-A2, and CD80 molecules. Infection ex vivo of purified mDC and pDC with MVA-C induced the expression of immunoregulatory pathways associated with antiviral responses, antigen presentation, T cell and B cell responses. Similarly, human whole blood or primary macrophages infected with MVA-C express high levels of proinflammatory cytokines and chemokines involved with T cell activation. The vector MVA-C has the ability to cross-present antigens to HIV-specific CD8 T cells in vitro and to increase CD8 T cell proliferation in a dose-dependent manner. The immunogenic profiling in mice after DNA-C prime/MVA-C boost combination revealed activation of HIV-1-specific CD4 and CD8 T cell memory responses that are polyfunctional and with effector memory phenotype. Env-specific IgG binding antibodies were also produced in animals receiving DNA-C prime/MVA-C boost. Our systems analysis of profiling immune response to MVA-C infection highlights the potential benefit of MVA-C as vaccine candidate against HIV/AIDS for clade C, the prevalent subtype virus in the most affected areas of the world.


Subject(s)
AIDS Vaccines/immunology , HIV-1/immunology , Immunity, Active/genetics , Systems Analysis , Vaccinia virus/immunology , Animals , Antibodies, Viral/blood , Antigen Presentation , Antigens, Viral/biosynthesis , Cell Proliferation , Cells, Cultured , Cross-Priming , Cytokines/metabolism , Dendritic Cells/immunology , Dendritic Cells/metabolism , Dendritic Cells/virology , Gene Expression , Gene Expression Profiling , HIV Envelope Protein gp120/immunology , HIV Infections/immunology , HIV Infections/prevention & control , Humans , Immunity, Innate/genetics , Mice , Mice, Inbred BALB C , Recombinant Proteins/biosynthesis , Signal Transduction/genetics , T-Lymphocytes/immunology , T-Lymphocytes/physiology , T-Lymphocytes/virology , Vaccination , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccinia virus/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL